craniofacial features [Tassabehji et al., 2005; Antonell et al., 2010] .
Here, we report the clinical and molecular characterization of a girl with a ∼ 1.3 Mb deletion that does not include the GTF2I gene and comprises partially the GTF2IRD1 gene.
Methods
A cohort of 37 patients referred to the Centro Nacional de Genética Médica (CENAGEM) because of a suspected diagnosis of WBS has been studied. Diagnostic confirmation by FISH was performed with a commercial Williams-Beuren syndrome region probe kit. Genomic DNA from the probands and their parents was extracted using standard methods. The current work has been approved by the Ethics Committee of CENAGEM. Informed consent was obtained from all families.
All DNA samples were tested for 7q11.23 microdeletion size using 2 different techniques: multiplex ligation-dependent probe amplification (MLPA) and real-time quantitative PCR (qPCR). The MLPA assay was performed using SALSA kit P029 (MRC Holland, http://www.mlpa.com), which contains 12 probes from the WBS chromosomal region ( fig. 1 a) and 20 control probes. For the MLPA analysis, 50 ng of DNA was used as instructed by the manufacturer's protocol. DNA from 3 healthy individuals was used as control. The PCR products were analyzed by capillary electrophoresis, and data normalization was performed by Coffalyser software (MRC Holland). Power SYBR Green PCR Master Mix (Applied Biosystems) was used for qPCR, as instructed by the manufacturer's protocol. Primers were designed for the amplification of DNA fragments located within and flanking the WBS chromosomal region and qPCR reactions were carried out as previously described . Control DNA fragments were located on alternate chromosomes ( fig. 1 a) . Samples were run in triplicate using standard conditions. Calculations were carried out by the comparative C t method.
To refine the distal breakpoint, we used several additional primer pairs to amplify the region between the more distal deleted fragment and the adjacent nondeleted segment (primer sequences are listed in online supplementary table 1, see www. k arger.com/doi/10.1159/000347167).
Results and Discussion
The WBS269-023A1 patient is the first daughter of healthy, nonconsanguineous parents and was 5 months old at the time of diagnosis. Family history showed ventricular septal defect in the father and atrial septal defect in a paternal uncle. The pregnancy was controlled and delivered by caesarean at 39 weeks of gestational age due to fetal distress.
Birth weight, length, and OFC were: 2.650 kg ( ∼ 3rd centile), 50 cm ( ∼ 50th centile) and 35 cm (50-75th centile), respectively. She was diagnosed with peripheral pulmonary stenosis and ventricular septal defect, and had a flat midface, depressed nasal bridge, anteverted nostrils, bitemporal narrowing, periorbital fullness, long philtrum, thick lips, and mild micrognathia ( fig. 2 ). When she was 2 years old, these facial features became accentuated as in typical WBS. She showed a mildly delayed development profile for her chronological age, based on the Gesell Developmental Schedules [Ball, 1977] . At 2 years of age, she also showed delays mainly in the adaptive fine motor development. Patterns of development for children between 15 months and 2 years old for motor, adaptive, language and personal-social areas were evaluated. The patient complied with the development guidelines envisaged by Gesell Schedules for the age of 15-18 months, except for some guidelines in the adaptive and fine motor development areas. For example, she was not able to turn the pages of a book and inserted no more than one cube on the form board. She also had speech delay with the incapacity to say 5 words, which is what we would expect for a child her age by the Gesell's standards. Unfortunately, she was too young to unambiguously determine her social behavior.
The molecular assessment of this patient showed an atypical short 7q11.23 deletion that partially included the GTF2IRD1 gene, but not GTF2I gene ( fig. 1 c) . The qPCR assay showed a deletion of the marker 4.12_GTF2IRD1, located 19 kb downstream of exon 1 of the GTF2IRD1 gene, but not of 4.1_GTF2IRD1 marker, 80 kb from exon 1.
To narrow the telomeric breakpoint, we performed a new qPCR assay using 3 additional markers located in between 4.12_GTF2IRD1 and 4.1_GTF2IRD1 ( fig. 1 d) . In this new qPCR assay, 4.12_GTF2IRD1 remained the most distal deleted marker, while 4.11_GTF2IRD1, located about 50 kb downstream exon 1, was the more proximal not deleted marker. This new assay showed that the distal breakpoint of the deletion was between 19-50 kb downstream of exon 1 of GTF2IRD1 gene, indicating that this patient had a deletion of ∼ 1.3 Mb ( fig. 1 d, e) . The MLPA assay did not detect the atypical deletion in this patient because the commercial kit does not provide probes located at the distal breakpoints.
Several reports have shown that the distal breakpoints of many atypical WBS deletions are clustered around the GTF2IRD1 gene [Gagliardi et al., 2003; Hirota et al., 2003; Tassabehji et al., 2005; Dai et al., 2009; Ferrero et al., 2010] ( fig. 1 b) . Such patients suggest that CLIP2, GTF2IRD1 and GTF2I are associated to the specific cognitive profile and craniofacial features [Tassabehji et al., 2005; Ferrero et al., c Profiles of qPCR assays for detection of deletion size. Relative DNA amplification of several markers was quantified for the WBS269-023A1 (green triangles) and 2 patients with classical WBS: WBS268-022A1 (red squares) and WBS270-024A1 (purple circles). WT is a reference sample (blue diamonds). d Profiles of qPCR assay to narrow the distal deletion breakpoint within the GTF2IRD1 gene. WBS269-023A1 (green large squares), WBS160 (purple triangles) carrying the classical deletion, WT2 (turquoise small squares), and WT (blue diamonds) are controls. e Mapping of atypical deletion of patient WBS269-023A1. The distal breakpoint is schematically represented about 19-50 kb downstream of exon 1 of the GTF2IRD1 gene. 4.12_GTF2IRD1 was the more distal deleted marker and 4.11_GTF2IRD1 was the first not deleted marker. 2010], although such evidences are debated and need further investigations [Vandeweyer et al., 2012] . A number of studies have established mice models of the more telomerically positioned WBS genes. Analysis of these mice has shown a series of phenotypes that share some intriguing parallels with WBS. A mouse model harboring a deletion between Clip2 and Gtf2ird1 showed craniofacial and dental abnormalities [Tassabehji et al., 2005] . Mice haploinsufficient for both Gtf2ird1 and Gtf2i are often growth retarded, and show hyploplasia of the mandible as well as other craniofacial defects resembling the anomalies and dental problems of WBS individuals [Enkhmandakh et al., 2009] . Finally, haploinsufficiency of GTF2IRD1 protein contributes to abnormalities of facial development, motor function and specific behavioral disorders that accompany WBS disease [Young et al., 2008; Howard et al., 2012; Schneider et al., 2012] . The phenotype of the patient reported here is in accordance with Dai et al. [2009] , who described a patient carrying a full deletion of GTF2IRD1 gene but preserving the GTF2I gene. Of note, these clinical manifestations do not completely fit with the data reported by other authors which showed that patients with WBS and smaller deletions preserving both GTF2IRD1 and GTF2I genes had mild craniofacial features [Gagliardi et al., 2003; Hirota et al., 2003; Tassabehji et al., 2005] ( table 1 ) .
Although the patient reported here does not have a complete deletion of GTF2IRD1 gene, it is possible that, as consequence of the rearrangement, the gene expression level is affected, as it has been demonstrated for the WBS flanking region genes . Nevertheless, as we do not have access neither to cell lines nor to fresh blood from the patient, this hypothesis has not been investigated in this work.
The identification of more atypical patients would enable better understanding of the individual role of each gene in the development of clinical features and the neuropsychological profiles. This is important because it gives us information about the pathogenic mechanisms of disease, which could contribute to the pursuit of new therapeutic treatments and eventually allow more precise prediction of the natural history in affected individuals. Because WBS is a rare disease with atypical deletions occurring only in 2% of patients, it is necessary to study a large population to obtain significant data, which would allow a more precise genotype-phenotype correlation and achieve more accurate conclusions. We encourage that larger consortia being developed to achieve this aim and the development of a set of quantitative measurements for clinical, cognitive and behavioral features in order to provide a far better mean of optimizing genotype-phenotype correlation.
